BOSTON, April 13, 2015 /PRNewswire/ -- PAREXEL
International (NASDAQ: PRXL), a leading global biopharmaceutical
services organization, today announced that it has been awarded a
2015 Gold Quill Merit Award from the International Association of
Business Communicators (IABC). The award recognizes the
Company for developing creative, engaging digital communications
with messaging that effectively reaches target audiences.
"Winning a Gold Quill Merit Award is a prestigious recognition
of our digital communication efforts," said Diana Martin, Vice President and Global Head of
Corporate Communications, PAREXEL. "The Company offers a
broad and innovative portfolio of products and services, and we are
focused on clearly and consistently communicating these offerings
for the benefit of our clients. As a result, PAREXEL.com has
become the most visited website among all contract research
organizations.[1]"
In 2014, PAREXEL launched a new corporate branding initiative
based on a commitment to excellence in meeting customer needs:
"Your Journey. Our Mission.™" To support that effort,
the Company developed a new corporate website and four targeted
social media properties on LinkedIn, Twitter, YouTube, and
Facebook.
"Our clinical research, consulting and technology customers are
increasingly seeking information about PAREXEL through online
vehicles," said Mark Anderson,
Global Director, Digital Communications, PAREXEL. "In
addition, they want to find that information quickly and easily.
We've created customer-centric content and digital properties that
address that need."
About IABC and the Gold Quill Awards Program
IABC is
comprised of more than 12,000 members in 100 chapters worldwide,
with awards programs at the chapter, region, and international
level. For more than 40 years, IABC's Gold Quill Awards have
recognized and awarded excellence in strategic communication
worldwide. IABC Gold Quill honors the dedication, innovation and
passion of communicators on a global scale. Since 2008, more than
5,000 projects have been entered in the Gold Quill Awards. The IABC
Gold Quill Awards program recognizes business communication
excellence globally, and is acknowledged as one of the most
prestigious awards programs in the industry. The IABC 2015
Gold Quill Awards will be presented at IABC's World Conference, to
be held in San Francisco, 14-17
June. More information on World Conference is available at:
http://wc.iabc.com/.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of expertise-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics, Inc. provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston, Massachusetts, PAREXEL operates in 81
locations in 51 countries around the world, and has approximately
16,530 employees. For more information about PAREXEL
International visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, and Your Journey. Our
Mission. are trademarks or registered trademarks of PAREXEL
International Corporation or its affiliates. All other
trademarks are the property of their respective owners.
This release contains "forward-looking" statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ materially from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from restructurings; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the
Company's ability to win new business, manage growth and costs, and
attract and retain employees; the Company's ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisition of ClinIntel Limited, or enter into new
lines of business; the impact on the Company's business of
government regulation of the drug, medical device and
biotechnology industry; consolidation within the pharmaceutical
industry and competition within the biopharmaceutical services
industry; the potential for significant liability to clients and
third parties; the potential adverse impact of health care reform;
and the effects of foreign currency exchange rate fluctuations and
other international economic, political, and other
risks. Such factors and others are discussed more fully
in the section entitled "Risk Factors" of the Company's Quarterly
Report on Form 10-Q for the quarter ended December 31,
2014 as filed with the Securities and Exchange Commission
on February 5, 2015, which "Risk Factors" discussion is
incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin,
PAREXEL
International
Tel: +1
781-434-5516
Email:
Diana.Martin@PAREXEL.com
Cristi Barnett, PAREXEL
International
Tel.: +1 781-434-4019
Email: Cristi.Barnett@PAREXEL.com
[1] Source: Alexa.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-wins-iabc-2015-gold-quill-merit-award-for-digital-communications-300064653.html
SOURCE PAREXEL International Corporation